Inhibrx | Investors - News Releases

News Releases

Month Year

Month Year

May 13, 2021

Inhibrx Reports First Quarter 2021 Financial Results
Mar 12, 2021

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist
Feb 1, 2021

Inhibrx Announces Participation in Upcoming Investor Conference
Jan 13, 2021

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

Registration-enabling study expected to begin dosing in the second or third quarter of this year
Jan 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

Show per page

Back To Top